<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942706</url>
  </required_header>
  <id_info>
    <org_study_id>BLOC-1</org_study_id>
    <nct_id>NCT02942706</nct_id>
  </id_info>
  <brief_title>Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC</brief_title>
  <official_title>Biomarker-Panel Guided Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After First Line Induction Therapy of Metastatic Colorectal Cancer (mCRC) : a Multicenter, Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment,
      versus continuation after 8 courses of induction therapy with cetuximab plus standard
      chemotherapy regimen (FOLFIRI or mFOLFOX6）in metastatic colorectal cancer (mCRC) patients.
      The maintenance treatments are continued until disease progression or untolerated toxicity.
      The aim of this study is to demonstrate that cetuximab monotherapy is non-inferior to
      continuation treatment, in those mCRC patients who responded to induction therapy(SD, PR, or
      CR), and carry biomarker-panels (KRAS, NRAS, BRAF, and PIK3CA) favor EGFR antibody.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is try to evaluate the effect of cetuximab monotherapy as maintenance treatment,
      versus continuation after 8 courses of induction therapy with cetuximab plus standard
      chemotherapy regimen (FOLFIRI or mFOLFOX6）in metastatic colorectal cancer (mCRC) patients.
      The maintenance treatments are continued until disease progression or untolerated toxicity.
      The aim of this study is to demonstrate that cetuximab monotherapy is non-inferior to
      continuation treatment, in those mCRC patients who responded to induction therapy(SD, PR, or
      CR), and carry biomarker-panels (KRAS, NRAS, BRAF, and PIK3CA) favor EGFR antibody.
      Furthermore, the mutation status of biomarker panel consist of KRAS, NRAS, HRAS, BRAF, EGFR,
      ERBB2, ERBB3, PIK3CA, PTEN, SMAD4, SMAD2, TGFBR2, cMET, Src, mTOR, VEGFR1, VEGFR2, EPHA2,
      MSI, TP53, ERCC1, ERCC5, KCNQ5, ILK, and Myc will be analyzed by NGS sequencing. The ctDNA as
      surrogate marker via liquid biopsy will be conducted before randomization, during maintenance
      treatment, and disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival 1 (PFS1)</measure>
    <time_frame>4 months</time_frame>
    <description>from randomization to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival 2 (PFS2)</measure>
    <time_frame>10 months</time_frame>
    <description>from signing informed consent to progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>24 months</time_frame>
    <description>drug related toxicity from signing informed consent to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>24 months</time_frame>
    <description>QoL from signing informed consent to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cet maintenance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab maintenance treatment following induction treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cet+chemo continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>anti-EGFR monoclonal antibody</description>
    <arm_group_label>Cet maintenance</arm_group_label>
    <arm_group_label>Cet+chemo continuation</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>Oxaliplatin+LV5FU2</description>
    <arm_group_label>Cet+chemo continuation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>Irinotecan+LV5FU2</description>
    <arm_group_label>Cet+chemo continuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Before the start of induction therapy:

        Inclusion Criteria:

          -  Histological proof of colorectal cancer (in case of a single metastasis, histological
             or cytological proof of this lesion should be obtained);

          -  Distant metastases which are either technically unresectable or no chance to reach NED
             (patients with only local recurrence are not eligible);

          -  Measurable disease (&gt; 1 cm on spiral CT scan or &gt; 2 cm on chest X-ray; liver
             ultrasound is not allowed). Serum CEA may not be used as a parameter for disease
             evaluation;

          -  Ongoing or planned first line induction therapy with 8 cycles of FOLFIRI or mFOLFOX6.

        Exclusion criteria

          -  Prior adjuvant treatment for stage II/III colorectal cancer ending within 6 months
             before the start of induction treatment

          -  Any prior adjuvant treatment after resection of distant metastases

          -  Previous systemic treatment for advanced disease

          -  RAS mutant mCRC

        At randomisation:

        Inclusion criteria:

          -  WHO performance status 0-1 (Karnofsky PS &gt; 70%);

          -  Disease evaluation with proven SD, PR or CR according to RECIST after 8 cycles of
             FOLFIRI or mFOLFOX6;

          -  Laboratory values obtained ≤ 2 weeks prior to randomisation: adequate bone marrow
             function (Hb &gt; 8.0 mmol/L, absolute neutrophil count &gt; 1.5 x 109/L, platelets &gt; 100 x
             109/L), renal function (serum creatinine ≤ 1.5x ULN and creatinine clearance, Cockroft
             formula, &gt; 30 ml/min), liver function (serum bilirubin ≤ 2 x ULN, serum transaminases
             ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver
             metastases);

          -  Life expectancy &gt; 24 weeks;

          -  Age: 18-75 years;

          -  Negative pregnancy test in women with childbearing potential;

          -  Expected adequacy of follow-up;

          -  Institutional Review Board approval;

          -  Written informed consent Exclusion criteria

          -  Chronic active infection;

          -  Any other concurrent severe or uncontrolled disease preventing the safe administration
             of study drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, MD &amp; Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Zhang, MD &amp; Ph. D</last_name>
    <phone>+86-13818332497</phone>
    <email>junzhang10977@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min Shi, MD &amp; Ph. D</last_name>
    <phone>+86-13512118830</phone>
    <email>shimin0412005@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Wasan H, Meade AM, Adams R, Wilson R, Pugh C, Fisher D, Sydes B, Madi A, Sizer B, Lowdell C, Middleton G, Butler R, Kaplan R, Maughan T; COIN-B investigators. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncol. 2014 May;15(6):631-9. doi: 10.1016/S1470-2045(14)70106-8. Epub 2014 Apr 3.</citation>
    <PMID>24703531</PMID>
  </reference>
  <reference>
    <citation>Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2.</citation>
    <PMID>22473155</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2016</study_first_submitted>
  <study_first_submitted_qc>October 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>MD &amp; Ph. D, Professor of Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

